Search

everythinglearnresearchcommunity

for

Search:↓

Substance P helps restore skin thickness and cell renewal when sensory nerves are reduced.

Presurgical models can effectively and affordably screen cancer prevention agents.

Minoxidil in FOAMIL is stable for at least 180 days at various concentrations.

The minoxidil and finasteride foam remains stable and effective for 180 days at room temperature.

Nilotinib can cause keratosis pilaris, a skin condition.

Nilotinib can cause skin issues like red bumps and hair loss.

Nilotinib can cause generalized keratosis pilaris.

The treatment combination is effective and generally safe for lung cancer.

A man treated with gefitinib for lung cancer grew new hair on his bald scalp.

Afatinib, neratinib, and zanubrutinib could be effective against KRASG12C-mutant tumors.

Ponatinib can cause a rare skin reaction that resolves with topical treatment and temporary drug discontinuation.

Erlotinib can cause significant but temporary hair loss in lung cancer patients.

Imatinib can cause hair loss due to lichen planopilaris.

Erlotinib can cause hair loss and texture changes.

Lenvatinib and sorafenib are generally safe but need dose adjustments due to side effects.

Excessive eyelash growth from erlotinib may indicate positive tumor response and help treat madarosis.

Anlotinib combined with taxane/capecitabine is more effective than bevacizumab for treating HER-2 negative metastatic breast cancer.

Breast cancer treatments work better with AR activation, improving results and reducing side effects.

Capivasertib improves survival in certain breast cancer cases but requires careful management of side effects.

Trametinib can effectively treat severe kaposiform lymphangiomatosis when other treatments fail.

Pemigatinib may be effective for treating ZMYM2::FGFR1 fusion-positive leukemia.

Erlotinib can cause hair loss as a side effect.

Gefitinib can cause skin problems, diarrhea, and nausea, but rarely causes severe lung disease or hair loss.

Nilotinib may cause gray hair to return to its original color.

A cancer drug called nilotinib might cause hair loss due to inflammation around hair follicles.

Gefitinib can cause hair and eyebrow darkening.

Targeted cancer therapies often cause serious skin problems that need careful management.

The document provides advice on how to recognize and treat skin-related side effects of cancer drugs known as EGFR inhibitors.

New chemotherapy drugs cause skin side effects, but treatments like minocycline and tetracycline can help reduce them.

Targeted cancer therapies can cause skin side effects, which should be treated early to help patients' quality of life and treatment adherence.